Navigation Links
Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
Date:12/11/2008

Adverse Reactions - The most common adverse reactions (>20%) during therapy with TYKERB plus capecitabine compared to capecitabine alone were diarrhea (65%, 40%), nausea (44%, 43%), vomiting (26%, 21%), palmar-plantar erythrodysesthesia (53%, 51%), rash (28%, 14%), and fatigue (46%, 47%).

The most common grade 3 and 4 adverse reaction (NCI CTC v3) with TYKERB plus capecitabine compared to capecitabine alone were diarrhea (14%, 10%) and palmar-plantar erythrodysesthesia (12%, 14%).

Please see full prescribing information, including BOXED WARNING.

Notes to Editors:

TYKERB(R) is a registered trademark of the GlaxoSmithKline group of companies in the United States and the countries outside of Europe.

FEMARA(R) is a registered trademark of Novartis in the United States and the European Union.

    Enquiries:

    Onsite Media
     enquiries:              Greg Clarke  - non US media only +1 610 405 0053
                             Ken Inchausti   - US media only  +1 267 809 7552

    UK Media enquiries:      Philip Thomson                  +44 20 8047 5502
                             Stephen Rea                     +44 20 8047 5502
                             Alice Hunt                      +44 20 8047 5502
                             Gwenan White                    +44 20 8047 5502

    US Media enquiries:      Nancy Pekarek                    +1 215 483 2839
                             Mary Anne Rhyne                  +1 919 483 2839
                             Sarah Alspach                    +1 215 751 7709

    European Analyst         David Mawdsley                  +44 20 8047 5564
    /Investor enquiries:     Sally Ferguson                  +44 20 8047 5543
                             Gary Davies                     +44 20 8047 5503

    US Analyst/ Investor
     enquiries:            
'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 On Saturday, October 25, 2014, ... annual family health and fitness fair ¡Vive tu vida! Get ... and good nutrition for better health and wellness for people ... free and open to the public, will be held at ... 9:00 am to 1:00 pm. , “¡Vive tu Vida! ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... Mission Viejo, CA (PRWEB) October 22, 2014 ... that Jay Cormier, Sr. Vice President of Sales, will ... at the upcoming Meetings Technology Expo on October 28, ... will also be hosting a booth as well as ... on how Lintelus Meeting can create a more engaging ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
... the sexes, findings show, , TUESDAY, Feb. 2 (HealthDay News) ... research indicates. , ""Our study shows that the relationship between ... in boys as it is in girls," study author Dr. ... Michigan, said in a university news release. "We found that ...
... ... Applicant Tracking System and Screening services. , ... Citrus Heights, CA (PRWEB) February 2, 2010 -- HR Allen ... efficient HRIS system, a web-based paperless Applicant Tracking System and an accurate, timely and ...
... , , FOUNTAIN HILLS, Ariz. , ... SNDZ), an innovative developer of safe and noninvasive therapies for ... and Scientific Social Solutions Charitable Foundation (S3) to provide medical ... former starting pitcher for the Boston Red Sox and New ...
... , , , LOS ANGELES , ... local, lost 143 lbs while eating fast food! He did this without ... to lose weight and have a career as a model/actor/comedian, LaVelle LaRue ... day. Like many of today,s busy Americans, he did not have the time ...
... it,s muscle tissue that needs examining, use MRI, expert says ... to assess the condition of heart arteries without putting a ... tomography -- more commonly called a CT scan -- is ... of studies has found. , "For ruling out coronary artery ...
... 2010 News media and others interested in the ... a series of American Chemical Society (ACS) Webinars, Your ... pertinent career topics impacting science and engineering professionals. ... Time, the free webinar will feature Carolyn Fisher, Regulatory ...
Cached Medicine News:Health News:Later Puberty Seen for Obese Boys 2Health News:HR Allen Provides Businesses with Three New Services. 2Health News:HR Allen Provides Businesses with Three New Services. 3Health News:Luis Tiant and Sunridge International Partner to Provide Medical Relief in Cuba: Former Star Pitcher for the Red Sox and Yankees Leads the Fight Against Glaucoma 2Health News:Luis Tiant and Sunridge International Partner to Provide Medical Relief in Cuba: Former Star Pitcher for the Red Sox and Yankees Leads the Fight Against Glaucoma 3Health News:From 301 lbs Diabetic to Fast Food Six Pack Abs 2Health News:CT Scans Deemed Best for Checking Heart Arteries 2Health News:CT Scans Deemed Best for Checking Heart Arteries 3Health News:ACS webinar features tips for finding and building a career in the food and flavor industries 2
(Date:10/22/2014)... 22, 2014 A new report ... (Product type, Form, End user, Application and Geography) - ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", ... Based on key trends tracked, it is anticipated that ... billion by 2020, registering a CAGR of 6.2% from ...
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
(Date:10/22/2014)... Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Second quarter overview: , Revenues of $53.9 million, ... Diluted EPS of $0.24, up 33% over last year,s ... revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... Internal Pipeline as DARA Program Enters ... SARM Program is Added, PRINCETON, N.J., Nov. 1 ... and nine months ended,September 30, 2007, and highlighted several ... since the beginning,of the quarter. During the third ...
... Calif., Nov. 1 IDM Pharma, Inc.,(Nasdaq: IDMI ... the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). The,trial ... cooperative,group study conducted by the Children,s Oncology Group (COG) ... patients originally treated in the Phase,3 trial. The results ...
Cached Medicine Technology:Pharmacopeia Announces Third Quarter 2007 Financial Results 2Pharmacopeia Announces Third Quarter 2007 Financial Results 3Pharmacopeia Announces Third Quarter 2007 Financial Results 4Pharmacopeia Announces Third Quarter 2007 Financial Results 5Pharmacopeia Announces Third Quarter 2007 Financial Results 6Pharmacopeia Announces Third Quarter 2007 Financial Results 7Pharmacopeia Announces Third Quarter 2007 Financial Results 8Pharmacopeia Announces Third Quarter 2007 Financial Results 9Pharmacopeia Announces Third Quarter 2007 Financial Results 10Pharmacopeia Announces Third Quarter 2007 Financial Results 11IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 2IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 3IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 5IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 6
... Control is a liquid control ... busy immunoassay laboratory. With a ... serum based control can replace ... products for immunoassay and therapeutic ...
Liquichek Immunology Control is a trilevel, liquid, comprehensive serum protein control with assayed values for a wide number of methods....
... Sample Detection Platform provides fully automated detection ... new platform for molecular pathology labs separates ... software features that deliver a high degree ... has the capacity to run two 96-well ...
Invacare 5 Oxygen Concentrator with Sens O2, 230 VAC - Intl....
Medicine Products: